We are live on
!
Find out more
ACA
Avoro Capital Advisors Portfolio holdings
AUM
$10.2B
1-Year Est. Return
149.19%
This Fund
S&P 500
This Quarter
Est. Return
+4.57%
1 Year Est. Return
+149.19%
3 Year Est. Return
+425.03%
5 Year Est. Return
+775.33%
10 Year Est. Return
+45,729.2%
AUM
$5.71B
AUM Growth
-$696M
(-11%)
Cap. Flow
-$760M
Cap. Flow
% of AUM
-13.31%
Top 10 Holdings %
Top 10 Hldgs %
73.58%
Holding
34
New
1
Increased
10
Reduced
17
Closed
4
Top Buys
| 1 |
AKRO
Akero Therapeutics
AKRO
|
+$159M |
| 2 |
MoonLake Immunotherapeutics
MLTX
|
+$56.2M |
| 3 |
uniQure
QURE
|
+$19.5M |
| 4 |
Vera Therapeutics
VERA
|
+$13.4M |
| 5 |
Alkermes
ALKS
|
+$13.4M |
Top Sells
| 1 |
BPMC
Blueprint Medicines
BPMC
|
+$361M |
| 2 |
Sarepta Therapeutics
SRPT
|
+$171M |
| 3 |
United Therapeutics
UTHR
|
+$91.2M |
| 4 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
+$82.5M |
| 5 |
Madrigal Pharmaceuticals
MDGL
|
+$43.9M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Ascendis Pharma A/S
ASND
$17.4B
| $860M | 15.05% |
4,980,000
-238,000
| -5% | -$38.8M |
|
|
2
United Therapeutics
UTHR
$22.7B
| $681M | 11.93% |
2,370,000
-305,000
| -11% | -$91.2M |
|
3
argenx
ARGX
$54.5B
| $648M | 11.34% |
1,175,000
-60,177
| -5% | -$34.9M |
|
|
4
Madrigal Pharmaceuticals
MDGL
$12.2B
| $567M | 9.94% |
1,875,000
-147,222
| -7% | -$43.9M |
|
5
Krystal Biotech
KRYS
$10.7B
| $366M | 6.4% |
2,660,000
-71,000
| -3% | -$10.4M |
|
6
Kymera Therapeutics
KYMR
$9.08B
| $286M | 5.01% |
6,555,555
+95,555
| +1% | +$3.29M |
|
|
APLS
7
DELISTED
Apellis Pharmaceuticals
APLS
| $212M | 3.71% |
12,222,222
| – | – |
|
|
RNAM
8
DELISTED
Avidity Biosciences
RNAM
| $200M | 3.51% |
7,050,000
-575,000
| -8% | -$17.1M |
|
|
9
MoonLake Immunotherapeutics
MLTX
$1.71B
| $196M | 3.43% |
4,150,000
+1,379,900
| +50% | +$56.2M |
|
|
AKRO
10
DELISTED
Akero Therapeutics
AKRO
| $187M | 3.27% |
+3,500,000
| New | +$159M |
|
|
SLNO
11
DELISTED
Soleno Therapeutics
SLNO
| $172M | 3.01% |
2,050,000
-475,000
| -19% | -$35.6M |
|
12
Xenon Pharmaceuticals
XENE
$6.55B
| $169M | 2.96% |
5,400,000
-341,666
| -6% | -$11.1M |
|
13
Arrowhead Research
ARWR
$10.4B
| $167M | 2.93% |
10,600,000
-511,111
| -5% | -$7.33M |
|
|
MRUS
14
DELISTED
Merus
MRUS
| $166M | 2.91% |
3,155,555
+155,555
| +5% | +$7.31M |
|
|
15
Vera Therapeutics
VERA
$2.98B
| $148M | 2.6% |
6,300,000
+598,100
| +10% | +$13.4M |
|
|
FOLD
16
DELISTED
Amicus Therapeutics
FOLD
| $103M | 1.81% |
18,000,000
-2,500,000
| -12% | -$16.1M |
|
|
17
Alkermes
ALKS
$8.65B
| $83M | 1.45% |
2,900,000
+450,000
| +18% | +$13.4M |
|
18
Ocular Therapeutix
OCUL
$2.16B
| $68.7M | 1.2% |
7,400,000
-660,000
| -8% | -$5.17M |
|
|
ETNB
19
DELISTED
89bio
ETNB
| $66.3M | 1.16% |
6,750,000
+400,000
| +6% | +$3.31M |
|
|
CNTA
20
DELISTED
Centessa Pharmaceuticals
CNTA
| $65.7M | 1.15% |
5,000,000
+950,000
| +23% | +$12M |
|
|
21
uniQure
QURE
$2.83B
| $50.5M | 0.88% |
3,625,000
+1,450,000
| +67% | +$19.5M |
|
22
Taysha Gene Therapies
TSHA
$1.55B
| $50.1M | 0.88% |
21,700,000
+1,700,001
| +9% | +$3.69M |
|
|
BPMC
23
DELISTED
Blueprint Medicines
BPMC
| $48.1M | 0.84% |
375,000
-3,475,000
| -90% | -$361M |
|
|
TRML
24
DELISTED
Tourmaline Bio
TRML
| $40.9M | 0.72% |
2,555,555
+130,555
| +5% | +$2.12M |
|
25
BioCryst Pharmaceuticals
BCRX
$2.52B
| $40.3M | 0.71% |
4,500,000
-4,200,000
| -48% | -$39.1M |
|
Similar funds
GI
IIM
RA
GT
VPIM
OIA
ECM
BEI